There are currently no generic versions of GLP-1s with the active ingredient semaglutide
The two drugs hit the gut from different directions
In 2026, Wegovys manufacturer, Novo Nordisk, secured approval for a GLP-1 tablet, commonly known as the Wegovy pill
Additionally, no provincial coverage means theres less negotiating power to reduce costs for the public system
and (4) conducting multinational phase IV trials to establish longitudinal safety and efficacy profiles.Together, these efforts aim to bridge the gap between mechanistic discovery and clinical translation, ultimately fostering a paradigm shift toward predictive, preventive, and personalized hepatology
This is a clinical decision that should be made in collaboration with your provider based on your progress, side effects, and goals